Action of vasoconstrictor hormones and calcium entry modulators on electrical activity and intracellular calcium of smooth muscle cells.
Ruegg
U T
UT
Preclinical Research, Sandoz Pharma Ltd, Basle, Switzerland.
Knot
H J
HJ
de Ree
M M
MM
Gahwiler
B H
BH
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D001464:Barium / Q000494:pharmacology; D017609:Barium Compounds; D002104:Cadmium / Q000494:pharmacology; D019256:Cadmium Chloride; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002460:Cell Line; D002712:Chlorides / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D009543:Nifedipine / Q000031:analogs & derivatives / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology*
D017609:Barium Compounds; D002121:Calcium Channel Blockers; D002712:Chlorides; D014662:Vasoconstrictor Agents; D002104:Cadmium; C024986:barium chloride; D014667:Vasopressins; D001464:Barium; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D009543:Nifedipine; D019256:Cadmium Chloride; C034600:darodipine